ZN-c3

selective oral Wee1 kinase inh. (300 mg QD)

Ph. II candidate for uterine serous carcinoma

from literature starting point

Journal of Medicinal Chemistry

Zentalis Pharmaceuticals, San Diego, CA, USA

The Zentalis Wee1 inhibitor, ZN-c3, is a highly selective kinase inhibitor that is currently being evaluated in Ph. II clinical trials in adult women with recurrent or persistent uterine serous…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.